Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary: To determine the clinical effect of zidovudine (AZT) compared to placebo in terms of time to progression to AIDS (i.e., occurrence of major opportunistic infections, dementia, and malignancies) or death. Initial drug assignment will be changed to open-label AZT for patients who experience a sustained decline in CD4 lymphocyte concentration to less than 200 cells/mm3, but analysis will be based on initial treatment assignment. To determine the immunologic effect of AZT compared to placebo in terms of time to drop in CD4 lymphocyte concentration of at least 25 percent from baseline assessment. To determine the antiviral effect of AZT compared to placebo in eradicating or suppressing HIV. Secondary: To determine the effect of AZT compared to placebo on the immune status of HIV-infected patients by comparing lymphocyte profiles and indices. To determine the long-term toxicities of AZT compared to placebo in terms of abnormalities in BL, hepatic function, renal function, skin, gastrointestinal system, and central nervous system. To describe the natural history of AIDS related complex (ARC) in placebo patients in terms of initial CD4 lymphocyte concentration and the Walter Reed staging system.
| Condition | Intervention |
|---|---|
|
HIV Infections |
Drug: Zidovudine |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patient must have AIDS related complex (ARC) as defined by Walter Reed stages, be ambulatory, and be able to give informed consent.
Exclusion Criteria
Co-existing Condition:
Patients with unstable disease characterized by the following are excluded:
- Hospitalization within the past 14 days.
- Major opportunistic infection, current or past.
- An active infection of onset during the past 30 days, as evidenced by symptoms, signs, or laboratory abnormalities such as:
- Temperature = or > 100.5 degrees F.
- Night sweats.
- Weight loss = or > 10 percent of body weight.
- Diarrhea (3 or more bowel movements/day).
- Persistent cough, shortness of breath, or dyspnea on exercise.
- Abnormal chest x-ray suggesting pneumonia or increased arterial-alveolar (A-a) gradient.
- Altered mental status, seizures, or focal neurologic signs.
- Abnormal computerized tomography (CT) scan or magnetic resonance imaging (MRI) suggestive of toxoplasmosis, peripheral mononuclear leukocytes, lymphoma, or other focal abnormality of the central nervous system (CNS).
- Abnormal cerebrospinal fluid (CSF) suggestive of cryptococcal, mycobacterial, or other meningitis. (The decision to perform invasive tests, such as lumbar puncture, specialized microbiological tests such as bone marrow culture for Mycobacteria or Histoplasma capsulatum, or specialized radiological tests such as CT scan or MRI should be based on clinical assessment of the patient.)
- Kaposi's sarcoma.
- Lymphoma; malignancy requiring chemotherapy.
- Dementia.
- Requiring hemodialysis or renal insufficiency or failure.
- Leukopenia.
- Thrombocytopenia.
Patients with the following are excluded:
- Unstable disease.
- Kaposi's sarcoma.
- Lymphoma; malignancy requiring chemotherapy.
- Dementia.
- Major opportunistic infection, current or past.
- Anemia (hemoglobin less than 9.5 g/dl).
Prior Medication:
Excluded within 1 month of study entry:
- Ribavirin or zidovudine (AZT) or other antivirals.
- Immunomodulating agents.
Contacts and Locations| United States, California | |
| Wadsworth Veterans Administration Med Ctr | |
| Los Angeles, California, United States, 90073 | |
| San Francisco Veterans Administration Med Ctr | |
| San Francisco, California, United States, 94121 | |
| United States, District of Columbia | |
| Veterans Administration Med Ctr | |
| Washington, District of Columbia, United States, 20422 | |
| Walter Reed Army Med Ctr | |
| Washington, District of Columbia, United States, 203075001 | |
| United States, Florida | |
| Dr Gordon Dickinson | |
| Miami, Florida, United States, 33136 | |
| United States, New York | |
| Dr Gigi Diamond / New York Veterans Administration | |
| New York, New York, United States, 10010 | |
| United States, North Carolina | |
| Veterans Affairs Med Ctr / Admin Only / Not For Patient Care | |
| Durham, North Carolina, United States, 27705 | |
| United States, Texas | |
| Houston Veterans Administration Med Ctr | |
| Houston, Texas, United States, 77030 | |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00002063 History of Changes |
| Other Study ID Numbers: | 016A, VA Study 298 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
Immune Tolerance AIDS-Related Complex Zidovudine |
Additional relevant MeSH terms:
|
Acquired Immunodeficiency Syndrome HIV Infections AIDS-Related Complex Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Zidovudine Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Anti-HIV Agents |
ClinicalTrials.gov processed this record on May 22, 2013